Podoplanin: An Emerging Cancer Biomarker and Therapeutic Target

Authors

Harini Krishnan, Stony Brook University
Julie Rayes, University of Birmingham
Tomoyuki Miyashita, University of Tokyo
Genichiro Ishii, University of Tokyo
Edward Retzbach, Rowan University School of Osteopathic Medicine
Stephanie Sheehan, Rowan University School of Osteopathic Medicine
Ai Takemoto, Japanese Foundation for Cancer Research
Yao-Wen Chang, Chang Gung University
Kazue Yoneda, Second Department of Surgery (Chest Surgery); University of Occupational and Environmental health; Kitakyushu Fukuoka Japan
Jun Asai, Kyoto Prefectural University of Medicine
Lasse Jensen, Linköping University
Lushun Chalise, Nagoya University
Atsushi Natsume, Nagoya University
Gary Goldberg, Rowan University School of Osteopathic Medicine

Document Type

Article

Version Deposited

Published Version

Publication Date

5-1-2018

Publication Title

Cancer Science

DOI

10.1111/cas.13580

Abstract

Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.

Recommended Citation

Krishnan H, Rayes J, Miyashita T, et al. Podoplanin: An emerging cancer biomarker and therapeutic target. Cancer Sci. 2018;109(5):1292-1299. doi: 10.1111/cas.13580. PMID: 29575529. PMCID: PMC5980289.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License